Real-time
Euronext Paris
03:12:32 2024-07-09 am EDT
|
5-day change
|
1st Jan Change
|
3.23
EUR
|
-2.56%
|
|
+10.62%
|
-61.32%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
22.84
|
23.75
|
151.6
|
289.9
|
141
|
85.85
|
Enterprise Value (EV)
1 |
26.04
|
31.26
|
130.6
|
193.2
|
105.9
|
125.7
|
P/E ratio
|
42.1
x
|
21.3
x
|
5.44
x
|
2.63
x
|
9.08
x
|
-2.42
x
|
Yield
|
-
|
-
|
1.2%
|
7.6%
|
-
|
-
|
Capitalization / Revenue
|
0.73
x
|
0.69
x
|
0.99
x
|
0.76
x
|
0.72
x
|
0.92
x
|
EV / Revenue
|
0.83
x
|
0.9
x
|
0.85
x
|
0.5
x
|
0.54
x
|
1.35
x
|
EV / EBITDA
|
31
x
|
17.4
x
|
2.84
x
|
1.36
x
|
2.28
x
|
-4.21
x
|
EV / FCF
|
-
|
-
|
7,609,916
x
|
2,624,223
x
|
-3,587,726
x
|
-2,830,320
x
|
FCF Yield
|
-
|
-
|
0%
|
0%
|
-0%
|
-0%
|
Price to Book
|
0.78
x
|
0.78
x
|
2.29
x
|
1.62
x
|
0.87
x
|
0.72
x
|
Nbr of stocks (in thousands)
|
9,135
|
9,135
|
9,135
|
11,014
|
10,220
|
10,281
|
Reference price
2 |
2.500
|
2.600
|
16.60
|
26.32
|
13.80
|
8.350
|
Announcement Date
|
5/6/19
|
4/30/20
|
4/21/21
|
4/25/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
31.3
|
34.64
|
153.9
|
382.5
|
196.6
|
92.98
|
EBITDA
1 |
0.8389
|
1.797
|
46.02
|
141.8
|
46.49
|
-29.82
|
EBIT
1 |
0.3718
|
1.245
|
45.73
|
140.7
|
38.88
|
-36.15
|
Operating Margin
|
1.19%
|
3.59%
|
29.72%
|
36.77%
|
19.78%
|
-38.88%
|
Earnings before Tax (EBT)
1 |
0.3714
|
0.8999
|
43.52
|
136.9
|
24.18
|
-39.68
|
Net income
1 |
0.5429
|
1.116
|
31.37
|
104
|
15.66
|
-36.95
|
Net margin
|
1.73%
|
3.22%
|
20.38%
|
27.19%
|
7.96%
|
-39.74%
|
EPS
2 |
0.0594
|
0.1221
|
3.050
|
10.01
|
1.520
|
-3.450
|
Free Cash Flow
|
-
|
-
|
17.16
|
73.61
|
-29.53
|
-44.39
|
FCF margin
|
-
|
-
|
11.15%
|
19.24%
|
-15.02%
|
-47.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
37.28%
|
51.91%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
54.7%
|
70.78%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
0.2000
|
2.000
|
-
|
-
|
Announcement Date
|
5/6/19
|
4/30/20
|
4/21/21
|
4/25/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
3.2
|
7.51
|
-
|
-
|
-
|
39.8
|
Net Cash position
1 |
-
|
-
|
21.1
|
96.7
|
35.1
|
-
|
Leverage (Debt/EBITDA)
|
3.819
x
|
4.179
x
|
-
|
-
|
-
|
-1.335
x
|
Free Cash Flow
|
-
|
-
|
17.2
|
73.6
|
-29.5
|
-44.4
|
ROE (net income / shareholders' equity)
|
1.87%
|
3.74%
|
64.8%
|
88.9%
|
9.33%
|
-25.5%
|
ROA (Net income/ Total Assets)
|
0.58%
|
1.79%
|
33%
|
44.5%
|
9.18%
|
-9%
|
Assets
1 |
93.44
|
62.23
|
94.97
|
233.7
|
170.5
|
410.5
|
Book Value Per Share
2 |
3.200
|
3.330
|
7.240
|
16.30
|
15.90
|
11.60
|
Cash Flow per Share
2 |
0.2000
|
0.2000
|
4.020
|
12.80
|
8.500
|
1.870
|
Capex
|
-
|
-
|
9.12
|
19
|
30.1
|
39.5
|
Capex / Sales
|
-
|
-
|
5.92%
|
4.97%
|
15.3%
|
42.53%
|
Announcement Date
|
5/6/19
|
4/30/20
|
4/21/21
|
4/25/22
|
4/28/23
|
4/30/24
|
|
1st Jan change
|
Capi.
|
---|
| -61.32% | 38.65M | | -8.00% | 11.78B | | -22.07% | 6.59B | | +27.13% | 5.46B | | -24.14% | 3.45B | | +4.11% | 2.5B | | +31.97% | 2.29B | | -67.03% | 2.21B | | -12.33% | 2.2B | | -17.96% | 1.59B |
Diagnostic & Testing Substances
|